Awakn Life Sciences (TSE:AWKN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Awakn Life Sciences has partnered with the University of Nottingham to conduct preclinical trials on a new chemical entity aimed at enhancing mental health treatments. The study, led by Dr. Madeleine King, focuses on the potential of aminoindane to improve social cognition and behaviors, particularly for PTSD. This collaboration marks a significant step in Awakn’s mission to develop innovative therapies for mental health disorders.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
